We here present a robust methodology to induce high-grade gliomas in mice that shows many similarities with high-grade glioma in patients. This transgenic mouse model combines high tumor take rate and rapid speed of induction (2-3 weeks) with the capacity of noninvasive assessment of tumor load using bioluminescence imaging. As demonstrated in a study with temozolomide, it can be used for intervention studies with almost the same convenience as the classical cell line based intracranial xenograft models. Transgenic models may provide a more accurate prediction of the efficacy of therapeutics than xenograft models, and the convenience of this model permits its implementation at an already early stage of preclinical evaluation. Research.
Introduction
High-grade gliomas, in particular glioblastoma multiforme (GBM), are the most common primary brain tumors in adults and among the deadliest of human cancers [1] . Their location and the extensive infiltration of tumor cells into surrounding pivotal brain structures is an impediment for all therapeutic interventions [2] . The real challenge in improving the survival of GBM patients is to design therapies against the numerous malignant cells that cannot be removed by surgical resection as they have migrated (deeply) into the normal surrounding brain parenchyma. Radiation therapy shows too many neurotoxic side effects to enlarge the high-dose target volume to include these glioma cells. Furthermore, most chemotherapeutic agents can not reach the invasive tumor cells because these reside in regions where the vasculature is largely intact with functional blood-brain barrier (BBB) properties. Appropriate mouse models of glioma may support the search for better therapies. We have, therefore, developed a glioma mouse model that is practically applicable for use in intervention studies.
Gliomas are classified from grade I (more benign) to grade IV (highly malignant; GBM) according to the WHO system [2] , which is based on histological features (e.g. mitotic activity, microvascular proliferation and pseudopalisading necrosis). GBMs can be distinguished into primary GBMs that rapidly arise without clinical evidence of a previously existing lower-grade lesion and secondary GBMs that develop through progression from lowgrade astrocytomas or anaplastic astrocytomas. Although primary and secondary GBMs are
Stereotactic intracranial injections
For lentiviral injections, 2 μl of virus suspension (p24 concentration of 4.5 μg/ml for GFAP-cre and 7.6 μg/ml for CMV-Cre) was injected intracranially in ;LucR conditional mice aged between 8 and 16 weeks. Injections were made using a stereotact as described in detail previously [18] .
In vivo bioluminescence imaging of intracerebral gliomas
Mice were monitored for the development of tumors by i.p injection of 150 mg/kg luciferin in PBS. Bioluminescence was measured using the Xenogen IVIS 200 Imaging system (Xenogen, Corporation, Alameda, CA, USA) as described in detail previously [18] .
Magnetic resonance imaging
Animals were given TMZ (100mg/kg/day p.o) for 5 or 6 days and were transported to ;LucR mice ( Figure 1 , Table 1 ). As a control, we also injected similar K-Ras studies, which was demonstrated in an efficacy study using temozolomide.
Lentiviral vectors are considered attractive CNS gene transfer tools due to their capacity to transduce dividing or nondividing cells in the brain [24] . To achieve targeted expression of Cre recombinase in glial cells, we equipped the lentivirus with a mouse GFAP promoter. Previously, it has been shown that in this way one can target transgene expression to glial cells in the brain [25] . Although we occasionally observed meningioma, or sarcomalike lesions after intracranial injections with CMV-Cre, the majority of the tumors were highgrade gliomas as induced by GFAP-Cre ( Figure 5B ). With CMV-Cre, tumor incidence was 100% and the latency period, significantly shorter than with GFAP-Cre. This may be due to a difference in infection efficiency between the two lentiviruses or caused by the fact that CMVCre but not GFAP-Cre can switch the conditional alleles in cell types that give rise to gliomas more efficiently. Recently, it has been reported that lentiviral vectors encoding floxed HRas v12 and AKT oncogenes gave rise to tumors in GFAP-Cre;p53 (+/-) transgenic mice with a latency of 80+ days [26] . In this study, it was shown that following intracranial injection of Although human gliomas rarely show RAS mutations [27] , virtually all malignant human gliomas show elevated levels of activated RAS [28] as a result of other lesions such as receptor tyrosine kinase mutations [29] , or inactivation of NF1 [30] and Rig [31] . Indeed,
several glioma mouse models have demonstrated the important role of RAS [32, 33] . In this study we used a conditional K-Ras V12 transgene to activate this commonly affected pathway in glioblastoma. A combination of continuous expression of mutant K-Ras and loss of p16 Ink4a /p19 Arf was sufficient to give rise to high-grade gliomas in about 35% of the animals injected with GFAP-Cre. Additionally, if combined with loss of function of p53, the tumor latency time was significantly reduced. Moreover, the incidence increased and tumors were mostly of grade IV (8/12), which is in agreement with previously studies [26, 34] . Interestingly, the implementation of p53 inactivation for developing mouse models of primary GBM has gained significance since recently published studies have shown that abrogation of the p53 pathway is also a key event in primary GBM [35,36]} and not, as was previously assumed, predominantly involved in initiation of low grade astrocytomas that progress later into secondary GBMs. In contrast to the deletion of p53, deletion of Pten does not appear to shorten the latency, although larger cohorts might have revealed subtle differences. The conditional K-Ras V12 transgene used in this study showed some spontaneous background of mammary tumors in females making tumor incidence curves less reliably. In this respect, use 
